Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Novo Nordisk, University of Washington deal

    Novo Nordisk A/S (CSE:NVO;NYSE:NVO), Bagsvaerd, Denmark University of Washington, Seattle, Wash. Business: Endocrine/Metabolic Novo Nordisk and the university partnered to develop therapies for diabetes and obesity. The…

    Published on 11/23/2015
  • Ophthotech, Novartis, Roche deal

    Ophthotech Corp. (NASDAQ:OPHT), New York, N.Y. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Ophthalmic Roches Genentech Inc. unit exercised its option to …

    Published on 11/23/2015
  • Oxford Gene, Baylor deal

    Oxford Gene Technology, Oxford, U.K. Baylor College of Medicine, Houston, Texas Business: Diagnostic, Genomics Oxford Gene Technology granted Baylor College of Medicines Baylor Miraca Genetics Laboratories rights to …

    Published on 11/23/2015
  • PeptiDream, Kyorin deal

    PeptiDream Inc. (Tokyo:4587), Tokyo, Japan Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan Business: Pharmaceuticals Kyorins Kyorin Holdings Inc. subsidiary will use PeptiDreams Peptide Discover Platform …

    Published on 11/23/2015
  • Perrigo, Mylan deal

    Perrigo Co. plc (NYSE:PRGO;Tel Aviv:PRGO), Dublin, Ireland Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Business: Autoimmune, Generics Perrigo shareholders rejected a hostile tender offer from Mylan. Perrigo said more than …

    Published on 11/23/2015
  • Pfizer, Celltrion deal

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Celltrion Inc. (KOSDAQ:068270), Incheon, South Korea Business: Biosimilars Pfizer returned to Celltrion rights to biosimilars of Rituxan rituximab and Herceptin trastuzumab. Pfizer…

    Published on 11/23/2015
  • Seek Ltd., NIH deal

    Seek Ltd., London, U.K. National Institutes of Health, Bethesda, Md. Business: Infectious Seek and NIHs National Institute of Allergy and Infectious Diseases (NIAID) partnered to study Seeks FLU-v universal influenza …

    Published on 11/23/2015
  • Servier, Pfizer deal

    Servier, Neuilly-sur-Seine, France Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer Servier granted Pfizer exclusive, worldwide co-development rights and U.S. commercialization rights to UCART19. The partners …

    Published on 11/23/2015
  • Shionogi, GlaxoSmithKline deal

    Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Infectious Shionogi and GlaxoSmithKline terminated a 2010 deal to jointly develop and commercialize cephem …

    Published on 11/23/2015
  • Stanford University, Eiger deal

    Stanford University, Stanford, Calif. Eiger Biopharmaceuticals Inc., San Carlos, Calif. Business: Endocrine/Metabolic Stanford University granted Eiger exclusive rights to Exendin (9-39) to treat post-bariatric surgical…

    Published on 11/23/2015
  • Summit Therapeutics, University of Oxford deal

    Summit Therapeutics plc (LSE:SUMM;NASDAQ:SMMT), Abingdon, U.K. University of Oxford, Oxford, U.K. Business: Musculoskeletal Summit and the University of Oxfords Isis Innovation Ltd. tech transfer arm extended through …

    Published on 11/23/2015
  • Telesta, Ipsen deal

    Telesta Therapeutics Inc. (TSX:TST;Pink:BNHLF), Belleville, Ontario Ipsen Group (Euronext:IPN;Pink:IPSEY), Boulogne-Billancourt, France Business: Cancer Telesta granted Ipsen exclusive, worldwide rights, excluding North…

    Published on 11/23/2015
  • University of Maryland, Glycocept deal

    University of Maryland, College Park, Md. Glycocept Inc., Baltimore, Md. Business: Antibodies The University of Maryland granted Glycocept exclusive, worldwide rights to develop and commercialize IP related to modifying…

    Published on 11/23/2015
  • Xoma, Agenus deal

    Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Agenus Inc. (NASDAQ:AGEN), Lexington, Mass. Business: Antibodies, Biomanufacturing Agenus will acquire Xomas antibody manufacturing facility and related assets. Xoma will …

    Published on 11/23/2015
  • Advaxis, Memorial Sloan Kettering deal

    Advaxis Inc. (NASDAQ:ADXS), Princeton, N.J. Memorial Sloan Kettering Cancer Center, New York, N.Y. Business: Cancer Advaxis and the center partnered to evaluate the immunological effects and antitumor activity of …

    Published on 11/16/2015
  • Affinivax, Nosocomial Vaccine deal

    Affinivax Inc., Cambridge, Mass. Nosocomial Vaccine Corp., Rockville, Md. Business: Infectious Nosocomial Vaccine (NVC) partnered with Affinivax to develop vaccines to prevent nosocomial infections. The collaboration …

    Published on 11/16/2015
  • Almirall, Allergan deal

    Almirall S.A. (Madrid:ALM), Barcelona, Spain Allergan plc (NYSE:AGN), Dublin, Ireland Business: Gastrointestinal Almirall granted Allergan exclusive rights to develop and commercialize Constella linaclotide in the EU, …

    Published on 11/16/2015
  • Astellas, Leo Pharma deal

    Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Leo Pharma A/S, Ballerup, Denmark Business: Dermatology Leo Pharma will acquire the global dermatology business of Astellas for EUR675 million ($726.6 million). Astellas …

    Published on 11/16/2015
  • Auris Medical, Kings College London deal

    Auris Medical Holding AG (NASDAQ:EARS), Zug, Switzerland Kings College London, London, U.K. Business: Other Auris and Kings College London partnered to discover and develop small molecules for Auris AM-102 project. AM-…

    Published on 11/16/2015
  • Basilea, Hikma Pharmaceuticals deal

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Hikma Pharmaceuticals plc (LSE:HIK), London, U.K. Business: Infectious Basilea granted Hikma exclusive rights to commercialize Zevtera ceftobiprole in the Middle …

    Published on 11/16/2015
  • Biogazelle, Isis Pharmaceuticals deal

    Biogazelle N.V., Zwijnaarde, Belgium Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Business: Cancer Biogazelle partnered exclusively with Isis to identify and validate targets to treat colon, liver and lung …

    Published on 11/16/2015
  • Biogen, Oklahoma Medical Research Foundation deal

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Oklahoma Medical Research Foundation, Oklahoma City, Okla. Business: Pharmacogenetics The foundation and Biogen partnered to develop biomarkers for Sjogrens syndrome. Biogen …

    Published on 11/16/2015
  • Eli Lilly, ImaginAb deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. ImaginAb Inc., Inglewood, Calif. Business: Cancer The companies partnered to study T cell-based immuno-oncology therapies. ImaginAb will conduct preclinical studies using…

    Published on 11/16/2015
  • Eli Lilly, WuXi PharmaTech deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. WuXi PharmaTech Inc. (NYSE:WX), Shanghai, China Business: Endocrine/Metabolic The companies partnered to develop and commercialize an undisclosed small molecule in China …

    Published on 11/16/2015
  • Emisphere, Novo Nordisk deal

    Emisphere Technologies Inc. (OTCBB:EMIS), Cedar Knolls, N.J. Novo Nordisk A/S (CSE:NVO;NYSE:NVO), Bagsvaerd, Denmark Business: Drug delivery, Endocrine/Metabolic Emisphere granted Novo Nordisk worldwide rights to …

    Published on 11/16/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993